Florida Onglyza Attorney - Jeffrey D. DeCarlo Gets Justice for Patients
Approved by the FDA in 2009, Onglyza is one of the newer Type 2 diabetes medications on the market today. Along with its sister medication, Kombiglyze, Onglyza has been linked to an increased risk of heart failure. If you or a loved one has been hurt by this dangerous drug, you may be able to pursue financial compensation.
Onglyza is a popular diabetes medication because it effectively controls the medical condition it is intended to treat and does not encourage weight gain, as many other diabetes medications do. Because of those benefits, millions of diabetic patients have opted for Onglyza, and it represents a major revenue source for its manufacturer, AstraZeneca.
Onglyza linked to heart failure, other deadly conditions
Lawsuits filed by people hurt by Onglyza allege that AstraZeneca knew that the medication was dangerous and continued to aggressively market the drug without informing doctors or patients of those risks. Studies published in 2015 showed that patients taking Onglyza were at a significantly elevated risk of heart failure, and the drug has also been linked to severe joint pain, pancreatitis and some types of pancreatic and thyroid cancers.
In 2015, the Food and Drug Administration (FDA) voted to require AstraZeneca to place warning labeling on Onglyza cautioning patients of the increased risk of heart failure. Symptoms of heart failure associated with Onglyza include:
- Trouble breathing
- Swelling of hands, feet or ankles
- Irregular heartbeat
- Persistent wheezing or cough
If you or a loved one has experienced symptoms of heart failure after taking Onglyza, you may be entitled to compensation. Attorney Jeffrey D. DeCarlo can help. A nationally recognized lawyer with over 20 years' experience handling complex injury cases, attorney DeCarlo stands up to pharmaceutical companies on behalf of injured patients throughout Florida.
Contact us today to protect your legal rights. Call (305) 572-0065 for a free, confidential consultation.